2-arylureidobenzoic acids: Selective noncompetitive antagonists for the homomeric kainate receptor subtype GluR5

被引:23
作者
Valgeirsson, J
Nielsen, EO
Peters, D
Varming, T
Mathiesen, C
Kristensen, AS
Madsen, U
机构
[1] Danish Univ Pharmaceut Sci, Dept Med Chem, DK-2100 Copenhagen, Denmark
[2] Danish Univ Pharmaceut Sci, Dept Pharmacol, DK-2100 Copenhagen, Denmark
[3] NeuroSearch AS, DK-2750 Ballerup, Denmark
关键词
D O I
10.1021/jm030428j
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of 2-arylureidobenzoic acids (AUBAs) was prepared by a short and effective synthesis, and the pharmacological activity at glutamate receptors was evaluated in vitro and in vivo. The compounds showed noncompetitive antagonistic activity at the kainate receptor subtype GluR5. The most potent compounds showed more than 50-fold selectivity for GluR5 compared to GluR6 and the AMPA receptor subtypes GluR1-4. The structure-activity relationships for the AUBAs showed distinct structural requirements for the substituents on the two aromatic ring systems. Only para-substituents were tolerated on the benzoic acid moiety (ring A), whereas ring B tolerated a variety of substituents, but with a preference for lipophilic substituents. The most potent compounds had a 4-chloro substituent on ring A and 3-chlorobenzene (6b), 2-naphthalene (8h), or 2-indole (8k) as ring B and had IC50 values of 1.3, 1.2, and 1.2,muM, respectively, in a functional GluR5 assay. Compound 6c (IC50 = 4.8 muM at GluR5) showed activity in the in vivo ATPA rigidity test, indicating that 6c has better pharmacokinetic properties than 8h, which was inactive in this test. The AUBAs are the first example of a series of noncompetitive GluR5-selective antagonists and may prove to be important pharmacological tools and leads in the search for therapeutic glutamatergic agents.
引用
收藏
页码:5834 / 5843
页数:10
相关论文
共 21 条
[1]   Kainate receptor agonists, antagonists and allosteric modulators [J].
Bleakman, D ;
Gates, MR ;
Ogden, AM ;
Mackowiak, M .
CURRENT PHARMACEUTICAL DESIGN, 2002, 8 (10) :873-885
[2]  
Bleakman D, 1996, MOL PHARMACOL, V49, P581
[3]   Ligands for glutamate receptors:: Design and therapeutic prospects [J].
Bräuner-Osborne, H ;
Egebjerg, J ;
Nielsen, EO ;
Madsen, U ;
Krogsgaard-Larsen, P .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (14) :2609-2645
[4]   Synthesis and receptor binding affinity of new selective GluR5 ligands [J].
Bunch, L ;
Johansen, TH ;
Bräuner-Osborne, H ;
Stensbol, TB ;
Johansen, TN ;
Krogsgaard-Larsen, P ;
Madsen, U .
BIOORGANIC & MEDICINAL CHEMISTRY, 2001, 9 (04) :875-879
[5]  
CHRISTENSEN JK, UNPUB J PHARM EXP TH
[6]   A hippocampal GluR5 kainate receptor regulating inhibitory synaptic transmission [J].
Clarke, VRJ ;
Ballyk, BA ;
Hoo, KH ;
Mandelzys, A ;
Pellizzari, A ;
Bath, CP ;
Thomas, J ;
Sharpe, EF ;
Davies, CH ;
Ornstein, PL ;
Schoepp, DD ;
Kamboj, RK ;
Collingridge, GL ;
Lodge, D ;
Bleakman, D .
NATURE, 1997, 389 (6651) :599-603
[7]  
Dingledine R, 1999, PHARMACOL REV, V51, P7
[8]   Ethyl (3S,4aR,6S,8aR)-6-(4-ethoxycarbonylimidazol-1-ylmethyl)decahydroiso-quinoline-3-carboxylic ester:: A prodrug of a GluR5 kainate receptor antagonist active in two animal models of acute migraine [J].
Filla, SA ;
Winter, MA ;
Johnson, KW ;
Bleakman, D ;
Bell, MG ;
Bleisch, TJ ;
Castaño, AM ;
Clemens-Smith, A ;
del Prado, M ;
Dieckman, DK ;
Dominguez, E ;
Escribano, A ;
Ho, KH ;
Hudziak, KJ ;
Katofiasc, MA ;
Martinez-Perez, JA ;
Mateo, A ;
Mathes, BM ;
Mattiuz, EL ;
Ogden, AML ;
Phebus, LA ;
Stack, DR ;
Stratford, RE ;
Ornstein, PL .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (20) :4383-4386
[9]  
Lee G. J, 2000, DRUGS, V59, P33
[10]  
Nielsen EO, 1999, J PHARMACOL EXP THER, V289, P1492